Clinical trials
Phase 3 Leukemia, Myelogenous, Chronic, BCR-ABL Positive trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
18 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 3 |
| 2008 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Terminated | 3 |
| Active, not recruiting | 2 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 9 |
| Pfizer | 2 |
| Ariad Pharmaceuticals | 1 |
| Ascentage Pharma Group Inc. | 1 |
| Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 1 |
| Bristol-Myers Squibb | 1 |
| Gamida Cell ltd | 1 |
| Gruppo Italiano Malattie EMatologiche dell'Adulto | 1 |
| University of Bologna | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 18 |
| Leukemia | 5 |
| Bone Marrow Diseases | 4 |
| Leukemia, Myeloid | 4 |
| Hematologic Neoplasms | 3 |
| Philadelphia Chromosome | 3 |
| Hematologic Diseases | 2 |
| Leukemia, Myeloid, Chronic-Phase | 2 |
| Myeloproliferative Disorders | 2 |
| Neoplasms by Histologic Type | 2 |
Trials
Showing 1 to 18 of 18. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.